Bulevirtide
- Generic Name
- Bulevirtide
- Brand Names
- Hepcludex
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2012558-47-1
- Unique Ingredient Identifier
- WKM56H3TLB
- Background
Hepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development of cirrhosis, severe decompensation of liver function, and an increased risk of mortality. Until recently, there have been extremely limited treatments available for Hepatitis D infection.
...
- Indication
Bulevirtide is indicated for the treatment of chronic Hepatitis D infection in HDV-RNA positive adult patients with compensated liver disease.
- Associated Conditions
- Hepatitis D
- Associated Therapies
- -
Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 150
- Registration Number
- NCT03852719
- Locations
- 🇩🇪
Universitätsklinikum Frankfurt Medizinische Klinik 1, Frankfurt am Main, Germany
🇮🇹Università di Modena e Reggio Emilia- Ospedale Civile S., Modena, Italy
🇺🇸Cornell University Well Madical College, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.